Hi @vnktshb ,
Management had clearly mentioned that ex of COVID drug sales, FY22 sales was 610-620 cr. They then guided for 15-20% growth in FY23 which means potential sales of 700-750 cr. In H1FY23, they did 340 cr. So they are broadly doing business in-line with their own guidance. Hope this provides a bit of context.
Disclosure: Invested (position size here, no transactions in last-30 days)